RecruitingPhase 2NCT06223048

A Study of AMDX-2011P in Participants With Primary Open Angle Glaucoma

A Phase 2, Randomized, Open Label Study of AMDX-2011P as a Retinal Tracer in Participants With Primary Open Angle Glaucoma

Sponsor

Amydis Inc.

Enrollment

50 participants

Start Date

Dec 7, 2023

Study Type

INTERVENTIONAL

Conditions

Primary Open Angle Glaucoma

Summary

The purpose of this research study is to assess the ability of AMDX- 2011P to identify amyloid deposits in the retina of participants with Primary Open Angle Glaucoma (POAG).

Eligibility

Min Age: 22 Years

Plain Language Summary

Simplified for easier understanding

This study is testing a new treatment called AMDX-2011P in people with primary open-angle glaucoma, the most common form of glaucoma, which causes gradual vision loss due to damage to the optic nerve. **You may be eligible if...** - You have been diagnosed with primary open-angle glaucoma in both eyes - You can maintain a steady gaze (fixate) during eye examinations - There is visible optic nerve damage in both eyes consistent with glaucoma **You may NOT be eligible if...** - You are unable to read or write - Your eye lens or media is too cloudy to obtain clear retinal images (cataracts by themselves are fine) - You have any eye disease other than glaucoma in the eye being studied Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.